OABI (OmniAb) Operating Cash Flow per Share : $-0.44 (TTM As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is OmniAb Operating Cash Flow per Share?

OmniAb's operating cash flow per share for the three months ended in Sep. 2024 was $-0.06. OmniAb's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.44.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of OmniAb was -922.20% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for OmniAb's Operating Cash Flow per Share or its related term are showing as below:

OABI' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -9.1 Med: -3.4 Max: 2.3
Current: -9.1

During the past 5 years, OmniAb's highest 3-Year average Operating Cash Flow per Share Growth Rate was 2.30% per year. The lowest was -9.10% per year. And the median was -3.40% per year.

OABI's 3-Year OCF Growth Rate is ranked worse than
66.05% of 1193 companies
in the Biotechnology industry
Industry Median: 3.6 vs OABI: -9.10

OmniAb Operating Cash Flow per Share Historical Data

The historical data trend for OmniAb's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OmniAb Operating Cash Flow per Share Chart

OmniAb Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.05

0.03

-0.05

-0.04

0.02

OmniAb Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Operating Cash Flow per Share	Get a 7-Day Free Trial											-0.06	-0.09	-0.17	-0.12	-0.06

Competitive Comparison of OmniAb's Operating Cash Flow per Share

For the Biotechnology subindustry, OmniAb's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OmniAb's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OmniAb's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where OmniAb's Price-to-Operating-Cash-Flow falls into.

OmniAb Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

OmniAb's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	2.347	/	99.683
	=	0.02

OmniAb's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Sep. 2024 )	=	Cash Flow from Operations (Q: Sep. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2024 )
	=	-6.578	/	102.393
	=	-0.06

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.44

OmniAb Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of OmniAb's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

OmniAb Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OmniAb Inc (NAS:OABI) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

5980 Horton Street, Suite 600, Emeryville, CA, USA, 94608

Website

https://www.omniab.com

OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

Executives

Matthew W Foehr	director, officer: President & CEO	11119 NORTH TORREY PINES RD #200, LA JOLLA CA 92037
Kurt A Gustafson	officer: EVP, Finance and CFO	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Charles S Berkman	officer: See Remarks	11085 NORTH TORREY PINES ROAD, SUITE 300, LA JOLLA CA 92037
Steven Love	director	C/O OMNIAB, INC., 5980 HORTON STREET, SUITE 600, EMERYVILLE CA 94608
Carolyn R Bertozzi	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Avista Capital Managing Member V, Llc	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V Gp, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners (offshore) V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Capital Partners V, L.p.	director, 10 percent owner	65 E. 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Jennifer R. Cochran	director	C/O LIGAND PHARMACEUTICALS INC, 3911 SORRENTO VALLEY BOULEVARD, STE 100, SAN DIEGO CA 92121
Thompson Dean	director, 10 percent owner	65 EAST 55TH STREET, 18TH FLOOR, C/O AVISTA CAPITAL PARTNERS, NEW YORK NY 10022
Avista Acquisition Lp Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
Avista Acquisition Gp Llc Ii	director, 10 percent owner	C/O AVISTA CAPITAL HOLDINGS, LP, 65 EAST 55TH STREET, 18TH FLOOR, NEW YORK NY 10022
David F Burgstahler	director, 10 percent owner	C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866